Advanced search
Publication Cover
Future Oncology Volume 15, 2019 - Issue 34
Submit an article Journal homepage
2,815
Views
6
CrossRef citations to date
0
Altmetric
Systematic Review

Augmenting the Randomized Controlled Trial with Real-World Data to Aid Clinical Decision Making in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Michael Moran1 Pfizer GmbH, Pfizer Oncology, Berlin10785, GermanyCorrespondence[email protected]
View further author information
,
Dana Nickens2 Pfizer Global, La Jolla, CA90630, USAView further author information
,
Katherine Adcock3 Pfizer Ltd, Walton Oaks, UKView further author information
,
Meg Bennetts4 Pfizer R&D UK Ltd, Sandwich, UKView further author information
,
Natalie Charnley5 Lancashire Teaching Hospitals, Cancer Services, Lancashire, UKView further author information
&
Kate Fife6 Cambridge University Hospital, Cancer Services, Cambridge, UKView further author information
Pages 3987-4001 | Received 18 Jul 2019, Accepted 24 Sep 2019, Published online: 18 Oct 2019

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Will Ince & Kate Fife. (2021) What is the Role of Real-World Data in Metastatic Renal Cell Cancer?. Future Oncology 17:30, pages 3905-3909.
Read now
Shouki Bazarbashi, Abdullah Alsharm, Faisal Azam, Hazem El Ashry & Jamal Zekri. (2020) The Clinical Significance of Routine Risk Categorization in Metastatic Renal Cell Carcinoma and its Impact on Treatment Decision-Making: A Systematic Review. Future Oncology 16:34, pages 2879-2896.
Read now
Ehab Abdou, Ravi M. Pedapenki, Mohamed Abouagour, Abdul R. Zar, Emad Dawoud, Dalia Elshourbagy, Humaid O. Al-Shamsi & Enrique Grande. (2020) Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 20:10, pages 831-840.
Read now
Lars H. Breimer, Petros Nousios, Louise Olsson & Hans Brunnström. (2020) Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm. Scandinavian Journal of Clinical and Laboratory Investigation 80:5, pages 360-369.
Read now

Articles from other publishers (2)

Marine Gross-Goupil, Lubomir Bodnar, Matthew T. Campbell, Agnieszka Michael, Balaji Venugopal, Jakub Żołnierek, Pascale Dutailly, Giuseppe Procopio & Laurence Albiges. (2024) Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence. Clinical Genitourinary Cancer 22:1, pages 84-97.
Crossref
Mohamed Nasr Mahmoud Hassan Farghaly, Ibrahim Sulaiman Mas’oud Al Ghaithi, Wael Abdel Rahman Mahamid, Abdallah Adlan, Saleh Mohammed AlGhamdi, Thamir M. Al Shammari, Nasser Mohammed Alqahtani, Suliman A. Al Ghnam, Marie Sleiman Awad Ibrahim, Hajer Al Mudaiheem, Mohamed Zahir Chouikrat, Yahia Aktham, Marwan Essam El Bagoury, Arun Jayarame Gowda, Khalid Al Moaikel & Nancy Syed Awad Abdallah. (2022) Promise of Real-World Evidence for Patient Centricity in Gulf Cooperation Council Countries: Call to Action. Drugs - Real World Outcomes 10:1, pages 1-9.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.